{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:36:55Z","timestamp":1772519815959,"version":"3.50.1"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Learning Objectives<\/jats:title><jats:p>After completing this course, the reader will be able to: Describe and weigh the available treatment options for the neoadjuvant therapy of soft tissue sarcoma of the limbs.Discuss the positive effects of preoperative treatment concepts on resection margins.Balance the adverse effects of pretreatment on subsequent operative morbidity.Interpret the weaknesses of currently available study results.<\/jats:p><jats:p>CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit\u2122 at CME.TheOncologist.com<\/jats:p><jats:p>Soft tissue sarcomas (STSs) form a heterogeneous group of malignant neoplasms arising in the mesenchymal connective tissues. They can develop at any anatomic site but 60% occur in the extremities. Initially, treatment of STS relied solely on excision. In the 1970s, Enneking et al. developed the concept of compartmental resection to reduce the local failure rate. Later, Rosenberg et al. demonstrated, in a randomized study, that there was no difference in local tumor control and disease-free survival (DFS) in patients treated with amputation versus limb-saving surgery followed by 50\u201370 Gy external-beam radiotherapy (EBRT).<\/jats:p><jats:p>A considerable proportion of patients present with locally advanced tumors as a primary or recurrent disease and cannot be resected with adequate clearance margins. These patients are threatened with amputation for complete tumor removal. Improvements in surgical techniques, such as microvascular muscle flaps, allow for the avoidance of limb loss in the majority of cases. However, the use of frozen sections to determine intraoperatively whether clear margins have been achieved is limited by the multiplanarity of resection specimens. Thus, local failure rates are 15%\u201325%, and preoperative measures to sterilize the invasive margin of sarcomas have been explored. High-dose preoperative EBRT for high-grade STS was developed, and its combination with intra-arterial or i.v. chemotherapy was reported to be effective. Recently, systemic chemotherapy combined with deep wave hyperthermia was shown to result in a longer DFS time in a large, randomized, phase III study. Treatment concepts differ significantly among centers and are influenced more by availability of technical equipment than by data. It is the aim of this review to elucidate the rationale of different regimens and analyze their potentials as well as weaknesses.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2007-0165","type":"journal-article","created":{"date-parts":[[2008,2,27]],"date-time":"2008-02-27T15:49:45Z","timestamp":1204127385000},"page":"175-186","source":"Crossref","is-referenced-by-count":56,"title":["Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Limbs: Which Treatment to Choose?"],"prefix":"10.1093","volume":"13","author":[{"given":"Peter","family":"Hohenberger","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology and Thoracic Surgery, University Hospital Mannheim, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech M.","family":"Wysocki","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Maria Sklodowska-Curie Memorial Institute of Oncology, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2008,2,1]]},"reference":[{"key":"2021122208161612400_R1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0959-8049(01)00083-1","article-title":"A randomised phase II study on neo-adjuvant chemotherapy for \u2018high-risk\u2019 adult soft-tissue sarcoma","volume":"37","author":"Gortzak","year":"2001","journal-title":"Eur J Cancer"},{"key":"2021122208161612400_R2","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1002\/1097-0142(19850601)55:11<2659::AID-CNCR2820551122>3.0.CO;2-Q","article-title":"Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma","volume":"55","author":"Suit","year":"1985","journal-title":"Cancer"},{"key":"2021122208161612400_R3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1992.10.1.52","article-title":"High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma","volume":"10","author":"Lienard","year":"1992","journal-title":"J Clin Oncol"},{"key":"2021122208161612400_R4","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S0959-8049(01)00183-6","article-title":"Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: Long-term results of a phase II study","volume":"37","author":"Issels","year":"2001","journal-title":"Eur J Cancer"},{"key":"2021122208161612400_R5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00000658-197609000-00004","article-title":"Limb salvage from a multidisciplinary treatment approach for skeletal and soft tissue sarcomas of the extremity","volume":"184","author":"Morton","year":"1976","journal-title":"Ann Surg"},{"key":"2021122208161612400_R6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/cncr.22114","article-title":"Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: Correlation with response and direct thermometry","volume":"107","author":"Gellermann","year":"2006","journal-title":"Cancer"},{"key":"2021122208161612400_R7","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.ijrobp.2004.08.036","article-title":"Histologic assessment of peritumoral edema in soft tissue sarcoma","volume":"61","author":"White","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18 suppl","key":"2021122208161612400_R8","first-page":"547s","article-title":"Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: A phase III randomised prospective trial (EORTC-ESHO intergroup trial)","volume":"25","author":"Issels","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122208161612400_R9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00000658-195810000-00009","article-title":"Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit","volume":"148","author":"Creech","year":"1958","journal-title":"Ann Surg"},{"key":"2021122208161612400_R10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/BF01655666","article-title":"The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities","volume":"12","author":"Di Filipo","year":"1988","journal-title":"World J Surg"},{"key":"2021122208161612400_R11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0748-7983(96)93114-5","article-title":"Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone","volume":"22","author":"Ginkel","year":"1996","journal-title":"Eur J Surg Oncol"},{"key":"2021122208161612400_R12","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s001040050132","article-title":"[Results of isolated hyperthermic extremity perfusion in soft tissue sarcomas within the scope of a multimodality treatment concept.]","volume":"67","author":"Schwarzbach","year":"1996","journal-title":"Chirurg"},{"key":"2021122208161612400_R13","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.1996.14.10.2653","article-title":"Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial","volume":"14","author":"Eggermont","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122208161612400_R14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1245\/ASO.2005.03.093","article-title":"Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs","volume":"12","author":"Lans","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"2021122208161612400_R15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1245\/ASO.2005.03.059","article-title":"Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg","volume":"12","author":"Gruenhagen","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"2021122208161612400_R16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1634\/theoncologist.11-4-397","article-title":"TNF-\u03b1 in cancer treatment: Molecular insights, antitumor effects, and clinical utility","volume":"11","author":"Horssen","year":"2006","journal-title":"The Oncologist"},{"key":"2021122208161612400_R17","first-page":"274","article-title":"Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma","volume":"1","author":"Posner","year":"1995","journal-title":"Cancer J Sci Am"},{"key":"2021122208161612400_R18","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1200\/JCO.1987.5.12.1942","article-title":"Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer","volume":"5","author":"Chapman","year":"1987","journal-title":"J Clin Oncol"},{"key":"2021122208161612400_R19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1126\/science.3764421","article-title":"Shock and tissue injury induced by recombinant human cachectin","volume":"234","author":"Tracey","year":"1986","journal-title":"Science"},{"key":"2021122208161612400_R20","first-page":"6","article-title":"Efficiency of recombinant human TNF in human cancer therapy","volume":"6","author":"Lejeune","year":"2006","journal-title":"Cancer Immun"},{"key":"2021122208161612400_R21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/01.sla.0000231723.81218.72","article-title":"Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin","volume":"244","author":"Menon","year":"2006","journal-title":"Ann Surg"},{"key":"2021122208161612400_R22","first-page":"323","article-title":"Angiographic observations before and after high dose TNF isolated limb perfusion in patients with extremity soft tissue sarcomas","volume":"20","author":"Eggermont","year":"1994","journal-title":"Eur J Surg Oncol"},{"key":"2021122208161612400_R23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/nbm.1940080506","article-title":"31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF\u03b1 + melphalan isolated limb perfusion","volume":"8","author":"Sijens","year":"1995","journal-title":"NMR Biomed"},{"key":"2021122208161612400_R24","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/cncr.10361","article-title":"31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors","volume":"94","author":"Kettelhack","year":"2002","journal-title":"Cancer"},{"key":"2021122208161612400_R25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/sj.bjc.6600707","article-title":"Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion","volume":"88","author":"Etten","year":"2003","journal-title":"Br J Cancer"},{"key":"2021122208161612400_R26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11912-001-0090-8","article-title":"Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: Credits, debits, and future perspectives","volume":"3","author":"Eggermont","year":"2001","journal-title":"Curr Oncol Rep"},{"key":"2021122208161612400_R27","doi-asserted-by":"crossref","first-page":"9455","DOI":"10.1158\/0008-5472.CAN-07-1599","article-title":"Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response","volume":"67","author":"Seynhaeve","year":"2007","journal-title":"Cancer Res"},{"key":"2021122208161612400_R28","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ejso.2005.07.003","article-title":"TNF dose reduction in isolated limb perfusion","volume":"31","author":"Gruenhagen","year":"2005","journal-title":"Eur J Surg Oncol"},{"key":"2021122208161612400_R29","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/annonc\/mdi229","article-title":"Limb salvage with isolated perfusion for soft tissue sarcoma: Could less TNF-alpha be better?","volume":"16","author":"Bonvalot","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122208161612400_R30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bjc.6690335","article-title":"Prerequisites for effective isolated limb perfusion using tumor necrosis factor alpha and melphalan in rats","volume":"80","author":"Wilt","year":"1999","journal-title":"Br J Cancer"},{"key":"2021122208161612400_R31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10434-999-0405-9","article-title":"Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-\u03b1 and melphalan","volume":"6","author":"Vrouenraets","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"2021122208161612400_R32","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1245\/ASO.2003.10.005","article-title":"Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan","volume":"10","author":"Hohenberger","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"2021122208161612400_R33","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/00003246-199605000-00007","article-title":"High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan","volume":"24","author":"Zwaveling","year":"1996","journal-title":"Crit Care Med"},{"key":"2021122208161612400_R34","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/00003246-200004000-00021","article-title":"Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan","volume":"28","author":"Kettelhack","year":"2000","journal-title":"Crit Care Med"},{"key":"2021122208161612400_R35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.1995.13.1.264","article-title":"Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan","volume":"13","author":"Thom","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122208161612400_R36","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","article-title":"Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions","volume":"18","author":"Wieberdink","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"2021122208161612400_R37","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0959-8049(97)00013-0","article-title":"Rhabdomyolysis and renal function impairment after isolated limb perfusion\u2014comparison between the effects of perfusion with rhTNF alpha and a \u2018triple-drug\u2019 regimen","volume":"33","author":"Hohenberger","year":"1997","journal-title":"Eur J Cancer"},{"key":"2021122208161612400_R38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0748-7983(96)90645-9","article-title":"Intracompartmental pressure during hyperthermic isolated limb perfusion for melanoma and sarcoma","volume":"22","author":"Hohenberger","year":"1996","journal-title":"Eur J Surg Oncol"},{"key":"2021122208161612400_R39","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0748-7983(98)80008-5","article-title":"Vascular complications of isolated limb perfusion","volume":"24","author":"Klicks","year":"1998","journal-title":"Eur J Surg Oncol"},{"key":"2021122208161612400_R40","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.4049\/jimmunol.136.7.2445","article-title":"Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma","volume":"136","author":"Ruggiero","year":"1986","journal-title":"J Immunol"},{"key":"2021122208161612400_R41","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00008390-199910000-00009","article-title":"Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicentre randomized phase II study","volume":"9","author":"Lienard","year":"1999","journal-title":"Melanoma Res"},{"key":"2021122208161612400_R42","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1742::AID-CNCR16>3.0.CO;2-G","article-title":"Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion","volume":"86","author":"Rossi","year":"1999","journal-title":"Cancer"},{"key":"2021122208161612400_R43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00002371-199909000-00004","article-title":"Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: Results of a phase I study","volume":"22","author":"Di Filippo","year":"1999","journal-title":"J Immunother"},{"key":"2021122208161612400_R44","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02071525","article-title":"Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs","volume":"16","author":"Thompson","year":"1992","journal-title":"World J Surg"},{"key":"2021122208161612400_R45","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/1097-0142(19940415)73:8<2140::AID-CNCR2820730819>3.0.CO;2-0","article-title":"Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas","volume":"73","author":"Rossi","year":"1994","journal-title":"Cancer"},{"key":"2021122208161612400_R46","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/bjc.1992.188","article-title":"Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities","volume":"65","author":"Guchelaar","year":"1992","journal-title":"Br J Cancer"},{"key":"2021122208161612400_R47","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/1097-0142(19890801)64:3<616::AID-CNCR2820640309>3.0.CO;2-8","article-title":"Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities","volume":"64","author":"Klaase","year":"1989","journal-title":"Cancer"},{"key":"2021122208161612400_R48","article-title":"Functional outcome after endoprosthetic limb-salvage therapy of primary bone tumours\u2014a comparative analysis using the MSTS score, the TESS and the RNL index","volume-title":"Int Orthop","author":"Tunn","year":"2007"},{"key":"2021122208161612400_R49","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0959-8049(99)00287-7","article-title":"Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register","volume":"36","author":"Trovik","year":"2000","journal-title":"Eur J Cancer"},{"key":"2021122208161612400_R50","first-page":"473","article-title":"Improved complete response rate with neoadjuvant chemotherapy and radiation for high grade extremity soft tissue sarcoma","volume":"13","author":"Eilber","year":"1994","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122208161612400_R51","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1245\/ASO.2005.03.064","article-title":"Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma","volume":"12","author":"Mack","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"2021122208161612400_R52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jso.20629","article-title":"Preoperative chemoradiation and flap reconstruction provide high local control and low wound complication rates for patients undergoing limb salvage surgery for upper extremity tumors","volume":"95","author":"Temple","year":"2007","journal-title":"J Surg Oncol"},{"key":"2021122208161612400_R53","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1245\/ASO.2006.02.005","article-title":"Isolated limb perfusion with tumor necrosis factor \u03b1 and melphalan for locally advanced soft tissue sarcoma: The value of adjuvant radiotherapy","volume":"13","author":"Thijssens","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"2021122208161612400_R54","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0360-3016(97)00923-1","article-title":"Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-\u03b1 and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma","volume":"40","author":"Olieman","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122208161612400_R55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2106\/00004623-197658030-00005","article-title":"The management of soft-tissue sarcomas of the extremities","volume":"58","author":"Simon","year":"1976","journal-title":"J Bone Joint Surg Am"},{"key":"2021122208161612400_R56","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00000658-198209000-00009","article-title":"The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy","volume":"196","author":"Rosenberg","year":"1982","journal-title":"Ann Surg"},{"key":"2021122208161612400_R57","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/1097-0142(19810501)47:9<2269::AID-CNCR2820470928>3.0.CO;2-J","article-title":"Preoperative radiation therapy for sarcoma of soft tissue","volume":"47","author":"Suit","year":"1981","journal-title":"Cancer"},{"key":"2021122208161612400_R58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1445-2197.1978.tb05806.x","article-title":"Limb salvage using preoperative intraarterial adriamycin and radiation therapy for extremity soft tissue sarcomas","volume":"48","author":"Morton","year":"1978","journal-title":"Aust N Z J Surg"},{"key":"2021122208161612400_R59","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJM199704033361402","article-title":"Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"2021122208161612400_R60","first-page":"124","article-title":"Wound healing after preoperative radiation for sarcoma of soft tissues","volume":"176","author":"Bujko","year":"1993","journal-title":"Surg Gynecol Obstet"},{"key":"2021122208161612400_R61","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00001622-200207000-00006","article-title":"Retroperitoneal sarcomas: Combined modality treatment approaches","volume":"14","author":"Pisters","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"2021122208161612400_R62","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/0360-3016(91)90337-4","article-title":"Preoperative and postoperative irradiation of soft tissue sarcomas: Effect of radiation field size","volume":"21","author":"Nielsen","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122208161612400_R63","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","article-title":"Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial","volume":"359","author":"O'Sullivan","year":"2002","journal-title":"Lancet"},{"key":"2021122208161612400_R64","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-1-4615-3082-4_5","article-title":"Surgical wound healing","volume":"67","author":"Springfield","year":"1993","journal-title":"Cancer Treat Res"},{"key":"2021122208161612400_R65","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/ejso.2001.1213","article-title":"Wound complications following pre-operative radiotherapy for soft tissue sarcoma","volume":"28","author":"Kunisada","year":"2002","journal-title":"Eur J Surg Oncol"},{"key":"2021122208161612400_R66","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00268-003-7115-4","article-title":"Preoperative radiotherapy for adult head and neck soft tissue sarcoma: Assessment of wound complication rates and cancer outcomes in a prospective series","volume":"27","author":"O'Sullivan","year":"2003","journal-title":"World J Surg"},{"key":"2021122208161612400_R67","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/(SICI)1096-9098(199602)61:2<90::AID-JSO2>3.0.CO;2-M","article-title":"Soft tissue sarcomas: Preoperative versus postoperative radiotherapy","volume":"61","author":"Cheng","year":"1996","journal-title":"J Surg Oncol"},{"key":"2021122208161612400_R68","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2002.03.084","article-title":"Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma","volume":"20","author":"Davis","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122208161612400_R69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.020","article-title":"Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma","volume":"75","author":"Davis","year":"2005","journal-title":"Radiother Oncol"},{"key":"2021122208161612400_R70","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/01.cco.0000161745.24887.82","article-title":"Preoperative vs postoperative radiation therapy for extremity soft tissue sarcoma: Controversy and present management","volume":"17","author":"Wolfson","year":"2005","journal-title":"Curr Opin Oncol"},{"key":"2021122208161612400_R71","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/1097-0142(20010915)92:6<1550::AID-CNCR1481>3.0.CO;2-C","article-title":"Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma","volume":"92","author":"Cormier","year":"2001","journal-title":"Cancer"},{"key":"2021122208161612400_R72","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2004.01.040","article-title":"Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas","volume":"22","author":"Pisters","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122208161612400_R73","first-page":"641","article-title":"Concomitant chemo-radiotherapy in the treatment of locally advanced and\/or metastatic soft tissue sarcomas: Experience of the National Cancer Institute of Genoa","volume":"10","author":"Toma","year":"2003","journal-title":"Oncol Rep"},{"key":"2021122208161612400_R74","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0360-3016(03)00186-X","article-title":"Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas","volume":"56","author":"DeLaney","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122208161612400_R75","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.02.5577","article-title":"Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514","volume":"24","author":"Kraybill","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122208161612400_R76","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF02743576","article-title":"[Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control.]","volume":"175","author":"Sauer","year":"1999","journal-title":"Strahlenther Onkol"},{"key":"2021122208161612400_R77","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1129::AID-CNCR11>3.0.CO;2-1","article-title":"High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a &gt;90% response rate and limb preservation","volume":"79","author":"Gutman","year":"1997","journal-title":"Cancer"},{"key":"2021122208161612400_R78","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s004020050314","article-title":"Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?","volume":"118","author":"Olieman","year":"1998","journal-title":"Arch Orthop Trauma Surg"},{"key":"2021122208161612400_R79","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1053\/ejso.2000.0979","article-title":"Limb salvage by neoadjuvant isolated perfusion with TNF\u03b1 and melphalan for non-resectable soft tissue sarcoma of the extremities","volume":"26","author":"Lejeune","year":"2000","journal-title":"Eur J Surg Oncol"},{"key":"2021122208161612400_R80","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/cncr.11648","article-title":"Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities","volume":"98","author":"Noorda","year":"2003","journal-title":"Cancer"},{"key":"2021122208161612400_R81","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/cncr.21802","article-title":"Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma","volume":"106","author":"Gruenhagen","year":"2006","journal-title":"Cancer"},{"key":"2021122208161612400_R82","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1245\/ASO.2005.12.038","article-title":"Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas","volume":"12","author":"Rossi","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"2021122208161612400_R83","first-page":"535","article-title":"Limb salvage by isolated limb perfusion (ILP) with tumor necrosis factor and melphalan in 246 patients with advanced soft tissue sarcoma: Results of 270 ILPs in 246 patients","volume":"18","author":"Eggermont","year":"1999","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2007-0165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2007-0165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/2\/175\/41831450\/oncolo_13_2_175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/2\/175\/41831450\/oncolo_13_2_175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T17:52:49Z","timestamp":1684259569000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/13\/2\/175\/6395845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,1]]},"references-count":83,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2008,2,1]]},"published-print":{"date-parts":[[2008,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2007-0165","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,2,1]]},"published":{"date-parts":[[2008,2,1]]}}}